NCT00548964

Continuation Ketamine in Major Depression

Continuation Intravenous Ketamine in Major Depressive Disorder - Modification: Lithium for Relapse Prevention

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: James Murrough · Academic / Other
• Sex: All
• Age: 21 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

As of May 21st, 2012, the purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for patients with treatment-resistant depression (TRD) who respond to an initial series of ketamine infusions. Ketamine is a Food and Drug Administration approved anesthetic (a drug used to produce loss of consciousness before and during surgery). Ketamine is not approved for the treatment of major depressive disorder and is considered experimental in this study.

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	Lithium	600-900mg of Li carbonate
DRUG	Ketamine	0.5mg/kg of ketamine

Timeline

• Start date: 2007-10-01
• Primary completion: 2013-07-01
• Completion: 2013-07-01
• First posted: 2007-10-25
• Last updated: 2014-05-23

Locations

1 site across 1 country: United States